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dergoing any study procedure. A total 260 patients fulﬁlling the
selection criteria were treated with either Lornoxicam 8mg- one
tablet b.d. or Diclofenac 50mg- one tablet t.d.s. for 4 weeks.
The primary efﬁcacy variables were improvements in Western
Ontario and McMasters (WOMAC) individual osteoarthritis (OA)
indices and Composite Index (for pain, stiffness and physical
function) and the Visual Analog Scale (VAS) scores (for pain).
Clinical evaluations were performed at baseline, 2nd week and 4th
week. Safety was monitored by incidence of treatment-emergent
adverse events, physical examination, assessments of vital signs
and routine laboratory tests.
Results: Of the 260 (130 in each groups) patients enrolled in
the study, 13 patients (7 in lornoxicam group and 6 in diclofenac
group) were lost to follow-up and were considered as drop-outs.
Thus the data of 247 (123 in lornoxicam and 124 in diclofenac
group) was included in the analysis. Over the 4-week study period
both drugs provided signiﬁcant sustained relief of osteoarthritic
symptoms compared to baseline. There was a reduction of
90.67% in mean pain score (WOMAC index) in lornoxicam group
and 88.9% in diclofenac group after 4 weeks of treatment. A
signiﬁcant reduction of 83.1% was observed in the mean VAS
pain score in lornoxicam group and 79.3% in diclofenac group
at the end of the 4th week. Onset of action rated at 2 weeks for
improvement in mean scores of stiffness, physical function, VAS
pain scores and mean total WOMAC Index scores was faster
in lornoxicam group as compared to diclofenac. Furthermore,
lornoxicam was better tolerated as compared to therapy with
diclofenac in this study. Lesser number of patients treated with
lornoxicam (13.1%) reported mild to moderate GI adverse events
compared to 17.6% patients treated with diclofenac. None of the
patients had cardiovascular adverse events such as edema or
increase in blood pressure.
Conclusions: The results of the present study conﬁrmed that
lornoxicam in a dose of 16mg/day had an early onset of action
and a better tolerability proﬁle as compared to diclofenac 150
mg/day in the treatment of adult Indian patients with osteoarthri-
tis. It could be therefore a safer and alternative option in the
symptomatic treatment of patients with osteoarthritis with lesser
dosing frequency.
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THE PREVENTIVE EFFECT OF PLATELET-RICH PLASMA
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Purpose: To investigate the therapeutic potential of adminis-
tration of gelatin hydrogel microspheres containing platelet-rich
plasma (PRP), by examining its effects on progression of os-
teoarthritis (OA) in a rabbit model.
Methods: PRP was prepared from rabbit blood by centrifuga-
tion. Gelatin hydrogel microspheres were prepared from bovine
gelatin using dehydrothermally cross-linking. To conﬁrm the an-
abolic effect of PRP in vivo, cartilage matrix gene expression was
examined after intra-articular administration of PRP contained in
gelatin hydrogel microspheres. The PRP in gelatin hydrogel mi-
crospheres was administered into the rabbit knee joint twice with
an interval of 3 weeks, beginning 4 weeks after anterior cruciate
ligament transaction (ACLT). Ten weeks after ACLT, gross mor-
phological and histological examinations of the knee joints were
performed.
Results: The puriﬁed PRP contained about 39.4 times the num-
ber of platelets contained in whole blood. In the knee joint, the
expression of proteoglycan core protein mRNA in the articular
cartilage increased after administration of PRP contained in mi-
crospheres. On the other hand, the expression did not increase
after administration of PRP only. Intra-articular injections of PRP
in gelatin hydrogel microspheres signiﬁcantly suppressed pro-
gression of OA in the ACLT rabbit model morphologically and
histologically. The independent administration of PRP or gelatin
hydrogel microspheres did not suppress the progression of OA.
Conclusions: PRP contains multiple growth factors, such as
TGF-β and PDGF at high levels and is used as an autologous
source of growth factors for soft tissue regeneration and bone
repair. A great advantage of PRP is that it is made from autolo-
gous blood, and thus does not induce an immune reaction. The
present study indicated that sustained release of growth factors
contained in PRP has preventive effects against OA progression.
These preventive effects appear to be due to stimulation of carti-
lage matrix metabolism, caused by the growth factors contained
in PRP.
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Purpose: The research was aimed at evaluating the effective-
ness of Theraﬂex-Advance (TA), (250 mg glucosamin sulphate,
200 mg chondroitin sulphate and 100 mg ibuprofen).
Methods: The ﬁrst group included 16 patients (aged 64,2±1,9
years) with knee osteoarthritis of II-III stages, according to
Kellgren-Lourenz. The control group included 16 patients with
the same diagnosis (aged 63,9±1,7 years), who took Theraﬂex
(TA) (500 mg glucosamin hydrochloride and 400 mg chondroitin
sulphate). The following methods of study were used: Mc-Gill
questionnaire, VAS, Leken index, Womac scales (WS), determi-
nation of life quality by EuroQol 5D scale.
Results: After two weeks of treatment, patients taking TA ob-
served a reliable decrease of pain syndrome by Womac scale
(before treatment 58,5±5,5; after two weeks 40,7±5,9; t=2,38;
p=0,037), decrease of constraint in movements (index before
treatment 57,8±6,5; after two weeks 36,7±6,3; t=2,65; p=0,022),
improvement of index of everyday activity (before treatment
64,6±4,1; after a fortnight - 44,0±6,1; t=2,82; p=0,017). Over
a month intensity of pain in the knee lowered in the group taking
TA, according to VAS scale (before treatment 55,0±3,1; over a
month 44,2±4,9; t=2,32; p=0,041), according to Womac scale
(before treatment 58,5±5,5; over a month 38,7±5,7; t=2,45;
p=0,032). Constraint of movement also decreased, according to
WS (before treatment 57,8±6,5; over a month 37,5±7,2; t=2,96;
p=0,013) and index of everyday activity improved (before treat-
ment 64,6±4,1; over a month 42,1±5,4; t=3,51; p=0,005). A
month after patients ceased taking the drug, intensity of pain
remained lower in comparison with indexes before treatment: by
VAS scale (before treatment 55,0±3,1; over a month - 39,0±4,1;
t=2,26; p=0,049), by WS (before treatment 58,5±5,5; over a
month -41,1±5,5; t=1,40; p=0,20). By contrast, the constraint
of movements increased (indexes after a month of treatment
-37,5±7,2; after two months - 47,0±6,6), and index of everyday
activity decreased according to WS (after a month - 42,1±5,4;
after two months - 49,4±5,3). However, the given indexes were
lower than before treatment (57,8±6,5 and 64,6±4,1, respec-
tively). In the group taking T, intensity of pain syndrome certainly
decreased after two months of treatment, according to VAS scale
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(before treatment - 50,9±3,9; after two months- 42,7±4,6; t=3,1;
p=0,011), Womac pain scale (before treatment - 47,0±5,3; after
two months- 30,4±6,5; t=2,89; p=0,016). The constraint of move-
ments decreased (before treatment 47,4±5,1; after two months-
35,9±6,6; t=2,67; p=0,023), and index of everyday activity im-
proved (before treatment 50,0±6,1; after two months- 38,3±6,3;
t=2,25; p=0,048).
Conclusions: Theraﬂex-Advance is instrumental in rapid de-
crease of intensity of the pain syndrome (after two weeks) in
patients with knee osteoarthritis. Over a month after cessation
of preparation taking, positive effect remains: knee pain is sig-
niﬁcantly lower in comparison with indexes before treatment;
constraint index increases and index of everyday activity ag-
gravates. Herewith, the given indexes remain lower than before
treatment. The analgesic effect after taking Teraﬂex-Advance be-
comes noticeable after two months when it is followed by the
essential decrease of constraint index, improvement of index of
everyday activity. Quality of life signiﬁcantly improved in patients
of both groups.
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Purpose: Topical formulations of diclofenac have been devel-
oped to provide local analgesic and anti-inﬂammatory effects
with minimal systemic exposure. The primary objective of this
study was to determine the long-term safety of diclofenac sodium
gel 1% (DSG) in patients with osteoarthritis (OA) of the knee.
Methods: To evaluate long-term safety of DSG, we have pooled
947 DSG patients from 3 studies of primary knee OA: a multicen-
ter, open-label 12-month study treating 1 or 2 knees (n=578) and
two previously completed double-blind 3-month trials treating 1
knee (n=369). The dose was 4 g of DSG 4 times per day in
all studies. Safety was assessed by monitoring adverse events
(AEs), clinical laboratory evaluations, vital signs, and physical
examinations. Assessment of pain/stiffness/physical function in
the target knee was a secondary objective and was evaluated
with the use of the Western Ontario and McMaster Universities’
OA (WOMAC) index.
Results: A total of 583 patients were enrolled in the open-label
study, including 292 naïve patients and 291 who continued from
the two 3-month double-blind studies. Of these, 350 treated 1
knee, 228 treated 2 knees and 5 could not be documented. Half
the patients were treated for 6 to 12 months, a third treated
12 months. The 369 DSG-treated patients from the double-blind
studies who did not continue into the open-label study were also
added to the safety population (n=947). Of all treated patients,
67.8% experienced a treatment-emergent adverse event (TEAE)
(65.5% of 719 patients in the 1-knee group and 75.0% of 228
patients in the 2-knee group). The most common TEAE was
headache (17.6% of treated patients, 16.6% and 21.1% of the 1-
knee and 2-knee groups, respectively). Application-site dermatitis
was reported by 10.5% of treated patients, 9.0% and 14.9%
of the 1-knee and 2-knee groups, respectively. Other common
TEAEs were arthralgia, back pain, and nasopharyngitis. The
incidence of serious adverse events (SAEs) was 3.1%, with
pneumonia the most frequent SAE. Discontinuation from the
study because of a TEAE occurred in 12.1% of treated patients
(9.7% and 19.7% of 1-knee and 2-knee groups, respectively).
Application-site dermatitis was the most frequent AE leading to
discontinuation (6.2% of treated patients, 4.7% and 11.0% of the
1-knee and 2-knee groups, respectively). Of the laboratory tests,
alanine aminotransferase (ALT) was elevated to >3 times the
upper limit of normal in 1% of patients. WOMAC assessments
showed sustained improvement in OA symptoms over 12 months
of treatment.
Conclusions: DSG was well tolerated. The overall rate of treat-
ment discontinuation due to TEAEs was low but higher in the
2-knee group. Mean measures of efﬁcacy showed improvement
in OA symptoms at each assessment over the 12 months of the
open-label study.
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C. Moser1, A.W. Baltzer1, S.A. Jansen2, R. Krauspe3,
P. Wehling1
1Centre for molecular Orthopaedics, Duesseldorf, Germany;
2Clinics for Surgery and Trauma Surgery, Mettmann, Germany;
3Heinrich-Heine University Hospital, Duesseldorf, Germany
Purpose: A new therapy, based on the intra-articular injec-
tion of autologous conditioned serum (ACS-Orthokine), is used
for osteoarthritis (OA) treatment. ACS is generated by incubat-
ing venous blood with medical grade glass beads. Peripheral
blood leukocytes produce elevated amounts of endogenous anti-
inﬂammatory cytokines such as interleukin-1 receptor antagonist
(IL-1Ra) and growth factors that are recovered in the serum
Methods: This document reports data from an observational,
prospective, cohort study conducted on patients with OA of the
knee. Subjects had completed a six-month randomized, con-
trolled, double-blind trial regarding the efﬁcacy and safety of in-
traarticular injection of ACS-Orthokine compared to Hyaluronan
(HA) and Saline. Previous analysis had conﬁrmed a superior re-
duction in WOMAC, Visual Analogue Scale of Pain (VAS), Global
Patient Assessment (GPA) scores after 6 months. A follow-up
evaluation was conducted to determine whether therapeutic ef-
fects were still present after 2 years.
Results: A total of 310 of the 345 patients who had participated
and ﬁnished the initial study were traced. Of these, 122 had
received additional therapy and were thus re-evaluated sepa-
rately using the last value carried forward method of imputation
(LOCF).
At 2-year follow-up evaluations, there were still statistically sig-
niﬁcant differences between the ACS-Orthokine and both control
groups with regard to WOMAC scores, VAS and GPA. The effect
size was still enormous.
Conclusions: The results demonstrate that treatment with ACS-
Orthokine results in a signiﬁcant therapeutic effect compared
to HA and saline at not only 6 months, but also at 2 years.
Remarkably, the placebo effect seen in patients who received
HA or saline, also persisted for the additional 18 months.
